Oral glutamine under assessment by EMA for sickle cell disease | Hospital Healthcare Europe

Oral glutamine under assessment by EMA for sickle cell disease | Hospital Healthcare Europe: Emmaus has announced that the company’s Marketing Authorisation Application (MAA) for Xyndari has been fully validated and is now under assessment by the European Medicines Agency (EMA) for th